A first-of-its-kind device for pancreatic cancer treatment has been approved by the U.S. Food and Drug Administration.

The Swiss biopharmaceutical company’s shares surged in after-hours trading after it said the FDA approved its Optune Pax ...

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to the abdomen in adult patients with locally advanced pancreatic cancer, ...

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...

Even before a tumor in the pancreas becomes discernible, an activated cancer gene actively remodels its future environment ...

Researchers say an immunotherapy they used represents a significant step forward and could lead to new treatment options, even for other forms of cancer ...

The scientists found that KLF5 had the greatest effect specifically promoting the growth and invasion of metastatic cells, ...

Scientists in Spain say they have uncovered a cure for pancreatic cancer in mice. The breakthrough could help people eventually.

The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a ...

First approved therapy for locally advanced disease in almost three decades ...